Cargando…

The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial

BACKGROUND: Preterm children with their aberrant gut microbiota and susceptibility to infections and inflammation constitute a considerable target group for probiotic therapy to generate the age-appropriate healthy microbiota. METHODS: 68 preterm neonates were randomized into five intervention group...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahkola, Ella-Noora, Rautava, Samuli, Hiltunen, Henni, Ross, Chandler, Lahti, Leo, Isolauri, Erika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589095/
https://www.ncbi.nlm.nih.gov/pubmed/37020105
http://dx.doi.org/10.1038/s41390-023-02560-y
_version_ 1785123719353466880
author Rahkola, Ella-Noora
Rautava, Samuli
Hiltunen, Henni
Ross, Chandler
Lahti, Leo
Isolauri, Erika
author_facet Rahkola, Ella-Noora
Rautava, Samuli
Hiltunen, Henni
Ross, Chandler
Lahti, Leo
Isolauri, Erika
author_sort Rahkola, Ella-Noora
collection PubMed
description BACKGROUND: Preterm children with their aberrant gut microbiota and susceptibility to infections and inflammation constitute a considerable target group for probiotic therapy to generate the age-appropriate healthy microbiota. METHODS: 68 preterm neonates were randomized into five intervention groups: Beginning from the median age of 3 days, 13 children received Lactobacillus rhamnosus GG (LGG) directly orally, and 17 via the lactating mother. 14 children received LGG with Bifidobacterium lactis Bb-12 (Bb12) orally, and 10 via the lactating mother. 14 children received placebo. The children’s faecal microbiota was assessed at the age of 7 days by 16S rRNA gene sequencing. RESULTS: The gut microbiota compositions of the children directly receiving the probiotic combination (LGG + Bb12) were significantly different from those of the children receiving the other intervention modes or placebo (p = 0.0012; PERMANOVA), the distinction being due to an increase in the relative abundance of Bifidobacterium animalis (P < 0.00010; ANCOM-BC), and the order Lactobacillales (P = 0.020; ANCOM-BC). CONCLUSION: The connection between aberrant primary gut microbiota and a heightened risk of infectious and non-communicable diseases invites effective microbiota modulation. We show that the direct, early, and brief probiotic intervention of LGG + Bb12 10(9) CFU each, is sufficient to modulate the gut microbiota of the preterm neonate. IMPACT: Preterm children have a higher risk of several health problems partly due to their aberrant gut microbiota. More research is needed to find a safe probiotic intervention to modify the gut microbiota of preterm children. The maternal administration route via breast milk might be safer for the newborn. In our study, the early and direct administration of the probiotic combination Lactobacillus rhamnosus GG with Bifidobacterium lactis Bb-12 increased the proportion of bifidobacteria in the preterm children’s gut at the age of 7 days, but the maternal administration route was not as effective.
format Online
Article
Text
id pubmed-10589095
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-105890952023-10-22 The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial Rahkola, Ella-Noora Rautava, Samuli Hiltunen, Henni Ross, Chandler Lahti, Leo Isolauri, Erika Pediatr Res Clinical Research Article BACKGROUND: Preterm children with their aberrant gut microbiota and susceptibility to infections and inflammation constitute a considerable target group for probiotic therapy to generate the age-appropriate healthy microbiota. METHODS: 68 preterm neonates were randomized into five intervention groups: Beginning from the median age of 3 days, 13 children received Lactobacillus rhamnosus GG (LGG) directly orally, and 17 via the lactating mother. 14 children received LGG with Bifidobacterium lactis Bb-12 (Bb12) orally, and 10 via the lactating mother. 14 children received placebo. The children’s faecal microbiota was assessed at the age of 7 days by 16S rRNA gene sequencing. RESULTS: The gut microbiota compositions of the children directly receiving the probiotic combination (LGG + Bb12) were significantly different from those of the children receiving the other intervention modes or placebo (p = 0.0012; PERMANOVA), the distinction being due to an increase in the relative abundance of Bifidobacterium animalis (P < 0.00010; ANCOM-BC), and the order Lactobacillales (P = 0.020; ANCOM-BC). CONCLUSION: The connection between aberrant primary gut microbiota and a heightened risk of infectious and non-communicable diseases invites effective microbiota modulation. We show that the direct, early, and brief probiotic intervention of LGG + Bb12 10(9) CFU each, is sufficient to modulate the gut microbiota of the preterm neonate. IMPACT: Preterm children have a higher risk of several health problems partly due to their aberrant gut microbiota. More research is needed to find a safe probiotic intervention to modify the gut microbiota of preterm children. The maternal administration route via breast milk might be safer for the newborn. In our study, the early and direct administration of the probiotic combination Lactobacillus rhamnosus GG with Bifidobacterium lactis Bb-12 increased the proportion of bifidobacteria in the preterm children’s gut at the age of 7 days, but the maternal administration route was not as effective. Nature Publishing Group US 2023-04-05 2023 /pmc/articles/PMC10589095/ /pubmed/37020105 http://dx.doi.org/10.1038/s41390-023-02560-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Research Article
Rahkola, Ella-Noora
Rautava, Samuli
Hiltunen, Henni
Ross, Chandler
Lahti, Leo
Isolauri, Erika
The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial
title The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial
title_full The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial
title_fullStr The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial
title_full_unstemmed The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial
title_short The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial
title_sort preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial
topic Clinical Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589095/
https://www.ncbi.nlm.nih.gov/pubmed/37020105
http://dx.doi.org/10.1038/s41390-023-02560-y
work_keys_str_mv AT rahkolaellanoora thepretermgutmicrobiotaandadministrationroutesofdifferentprobioticsarandomizedcontrolledtrial
AT rautavasamuli thepretermgutmicrobiotaandadministrationroutesofdifferentprobioticsarandomizedcontrolledtrial
AT hiltunenhenni thepretermgutmicrobiotaandadministrationroutesofdifferentprobioticsarandomizedcontrolledtrial
AT rosschandler thepretermgutmicrobiotaandadministrationroutesofdifferentprobioticsarandomizedcontrolledtrial
AT lahtileo thepretermgutmicrobiotaandadministrationroutesofdifferentprobioticsarandomizedcontrolledtrial
AT isolaurierika thepretermgutmicrobiotaandadministrationroutesofdifferentprobioticsarandomizedcontrolledtrial
AT rahkolaellanoora pretermgutmicrobiotaandadministrationroutesofdifferentprobioticsarandomizedcontrolledtrial
AT rautavasamuli pretermgutmicrobiotaandadministrationroutesofdifferentprobioticsarandomizedcontrolledtrial
AT hiltunenhenni pretermgutmicrobiotaandadministrationroutesofdifferentprobioticsarandomizedcontrolledtrial
AT rosschandler pretermgutmicrobiotaandadministrationroutesofdifferentprobioticsarandomizedcontrolledtrial
AT lahtileo pretermgutmicrobiotaandadministrationroutesofdifferentprobioticsarandomizedcontrolledtrial
AT isolaurierika pretermgutmicrobiotaandadministrationroutesofdifferentprobioticsarandomizedcontrolledtrial